Congratulations for this well deserved Distinguished Alumnus Award Larry Norton MSK Department of Medicine Memorial Sloan Kettering Cancer Center. You are an inspiring leader, a dedicated physician and an amazing mentor to so many at MSK and beyond. Thank you

Despite advances in the treatment of breast cancer, challenges remain, such as the development of resistance to existing therapies, serious adverse events, and suboptimal treatment adherence. #bcsm | Komal Jhaveri Memorial Sloan Kettering Cancer Center

ow.ly/pHlK50L9uBC

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR+/HER2- metastatic breast cancer vs other variations and monotherapies of the 3 drugs. #mbc #bcsm | Komal Jhaveri Memorial Sloan Kettering Cancer Center

ow.ly/8Ee350KT6fm

Zanidatamab Zovodotin Showcases Promising Safety, Activity in HER2+ Solid Cancers Komal Jhaveri Memorial Sloan Kettering Cancer Center ESMO - Eur. Oncology #ESMO2022
ow.ly/SYhN50KPogs

We are certainly striving for that for our patients Memorial Sloan Kettering Cancer Center #endcancer

Promising preliminary data from 1st-in-human trial of ZW49 (anti-HER2 bispecific ADC) monotherapy, show antitumor activity @ 2.5mg/kg Q3W in heavily pretreated pts with HER2+ cancers (cORR 31%) with manageable toxicity (no interstitial lung disease).

Komal Jhaveri #ESMO22

Komal Jhaveri discusses #ADC combos in HR+ #bcsm :

📍 Can we affect cell surface expression of target?

🚙 Roadmap for HR+ includes ET until resistance then ADCs now

📣Future needs analysis of biomarkers and resistance mechanisms

#ESMO22 OncoAlert

Exciting work! Congratulations!

TUXEDO-1. T-DXd in 15 pts w untreated/progressive HER2+ Brain Mets. 2 intracranial CRs, 9 intracranial PRs with a best overall intracranial response rate of 73.3%.

Best ADC intracranial activity to date in BC! DESTINY-12 Phase IIIb/IV pending. #BCSM

pubmed.ncbi.nlm.nih.gov/35941372/

So exciting for our patients and everyone who made this possible! ADCs are here to stay! Cheers to many more!

Optimized Therapy Requires More Than Binary Understanding of HER2 Positivity in Metastatic Breast Cancer Komal Jhaveri Memorial Sloan Kettering Cancer Center PER #IBCEast #bcsm ow.ly/XkNe50JXsMR

#DB04 out in print now, #TDXd for #HER2low #bcsm .

Actionable across traditional #TNBC and #HR + phenotypes.

Congrats Dr. Modi, ⁦Aleix Prat #PrecisionOncology⁩, ⁦Hope Rugo⁩, etc.

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Br Ca | NEJM nejm.org/doi/full/10.10…

Endocrine therapy:Maverick! What's new in ER+ breast cancer? A lot cooking: oral SERD/SERCA/PROTAC..Our vision along with pivotal data in the field here (updated ASCO22)
📍cancertreatmentreviews.com/article/S0305-… Memorial Sloan Kettering Cancer Center production Komal Jhaveri Sarat Chandarlapaty Lab Elaine Walsh #bcsm

A lot going on in the ET field: elacestrant with positive data, five oral SERDS in phase 3 testing and many new drug classes/combos being developed. Wonderfully reviewed by Emanuela Ferraro, MD & the Sloan-Kettering team.
cancertreatmentreviews.com/article/S0305-…

In case you missed it, updated results from the eNRGy study presented at #ASCO22 ! Zeno ORR of 34% (27/79) across tumor types & 42% (8/19) in PDAC. Median DOR of 9.1 mo and extremely well tolerated. Zeno has the potential to become new SOC for this unmet clinical need.